Cargando…

Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells

Melanoma is a molecularly heterogeneous disease with many genetic mutations and altered signaling pathways. Activating mutations in the BRAF oncogene are observed in approximately 50% of cutaneous melanomas and the use of BRAF inhibitor (BRAFi) compounds has been reported to improve the outcome of p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fratangelo, Federica, Camerlingo, Rosa, Carriero, Maria Vincenza, Pirozzi, Giuseppe, Palmieri, Giuseppe, Gentilcore, Giusy, Ragone, Concetta, Minopoli, Michele, Ascierto, Paolo Antonio, Motti, Maria Letizia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065454/ https://www.ncbi.nlm.nih.gov/pubmed/29956724 http://dx.doi.org/10.3892/ijo.2018.4457

Ejemplares similares

Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells
por: Ragone, Concetta, et al.
Publicado: (2017)

Role of Microenvironment on the Fate of Disseminating Cancer Stem Cells
por: Ingangi, Vincenzo, et al.
Publicado: (2019)

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
por: Caputo, Emilia, et al.
Publicado: (2014)

MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors
por: Motti, Maria Letizia, et al.
Publicado: (2020)

Controversial Role of Kisspeptins/KiSS-1R Signaling System in Tumor Development
por: Fratangelo, Federica, et al.
Publicado: (2018)

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
por: Caputo, Emilia, et al.
Publicado: (2015)

Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model
por: Lemasson, Benjamin, et al.
Publicado: (2016)

Melanoma: BRAFi Rechallenge
por: Kosmidis, Christoforos S., et al.
Publicado: (2023)

ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts
por: Yuan, Alice L., et al.
Publicado: (2018)

Evaluation of ABT-888 in the amelioration of α-synuclein fibril-induced neurodegeneration
por: Hastings, Lyndsay, et al.
Publicado: (2022)

The PARP inhibitor ABT-888 potentiates darbazine-induced cell death in carcinoids
por: Somnay, Yash, et al.
Publicado: (2016)

NF-κB as potential target in the treatment of melanoma
por: Madonna, Gabriele, et al.
Publicado: (2012)

Therapeutic Strategies Targeting Urokinase and Its Receptor in Cancer
por: Masucci, Maria Teresa, et al.
Publicado: (2022)

Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors
por: Masucci, Maria Teresa, et al.
Publicado: (2023)

The urokinase receptor-derived cyclic peptide [SRSRY] suppresses neovascularization and intravasation of osteosarcoma and chondrosarcoma cells
por: Ingangi, Vincenzo, et al.
Publicado: (2016)

Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas
por: Carriero, Maria Vincenza, et al.
Publicado: (2017)

Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma
por: Barazzuol, Lara, et al.
Publicado: (2013)

PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models
por: Guillot, Clément, et al.
Publicado: (2014)

Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion
por: Minopoli, Michele, et al.
Publicado: (2019)

Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations
por: Gentilcore, Giusy, et al.
Publicado: (2013)

Main roads to melanoma
por: Palmieri, Giuseppe, et al.
Publicado: (2009)

PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression
por: Mariano, Germano, et al.
Publicado: (2015)

Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888
por: Tuli, Richard, et al.
Publicado: (2014)

ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells
por: Balvers, Rutger K, et al.
Publicado: (2015)

Poly (ADP-Ribose) Polymerase Inhibitor, ABT888, Improved Cisplatin Effect in Human Oral Cell Carcinoma
por: Paterniti, Irene, et al.
Publicado: (2021)

Modeling Pharmacodynamic Response to the Poly(ADP-Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells
por: Ji, Jiuping, et al.
Publicado: (2011)

Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?
por: Prasad, Chandra Prakash, et al.
Publicado: (2015)

Changes in the Transcriptome and Chromatin Landscape in BRAFi-Resistant Melanoma Cells
por: Reddi, Kiran Kumar, et al.
Publicado: (2022)

Structure-function relationship of an Urokinase Receptor-derived peptide which inhibits the Formyl Peptide Receptor type 1 activity
por: Minopoli, Michele, et al.
Publicado: (2019)

Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study
por: Munasinghe, Wijith, et al.
Publicado: (2016)

Cyclization of the Urokinase Receptor-Derived Ser-Arg-Ser-Arg-Tyr Peptide Generates a Potent Inhibitor of Trans-Endothelial Migration of Monocytes
por: Yousif, Ali Munaim, et al.
Publicado: (2015)

Proteomics and Phosphoproteomics Profiling of Drug-Addicted BRAFi-Resistant Melanoma Cells
por: Li, Bohui, et al.
Publicado: (2021)

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma
por: Krayem, Mohammad, et al.
Publicado: (2018)

The AhR‐SRC axis as a therapeutic vulnerability in BRAFi‐resistant melanoma
por: Paris, Anaïs, et al.
Publicado: (2022)

Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy
por: Masucci, Maria Teresa, et al.
Publicado: (2019)

The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma
por: Thompson, Elizabeth L., et al.
Publicado: (2021)

Harnessing host innate immunity may combat acquired resistance to BRAFi
por: Tan, Thomas, et al.
Publicado: (2014)

NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors
por: Cecchini, Michael, et al.
Publicado: (2023)

Sorafenib-Loaded PLGA Carriers for Enhanced Drug Delivery and Cellular Uptake in Liver Cancer Cells
por: Caputo, Tania Mariastella, et al.
Publicado: (2023)

miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma
por: Stark, Mitchell S., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_gcrmcb0cqmicg26hlaaaj9uq5h